Day: August 5, 2021

August 5, 2021 SBM Offshore is pleased to announce a EUR150 million (c. US$180 million) share repurchase program, effective from August 5, 2021. The objective of the program is to reduce share capital and, in addition, to provide shares for regular management and employee share programs. The repurchase program is expected to be completed within the year 2021, and it will be accomplished under the authorization granted by the Annual General Meeting of the Company on April 7, 2021. The execution of the share repurchase program will be done under the terms of an engagement letter with a third party, performed in compliance with the safe harbor provisions for share repurchases, and therefore transactions may be carried out during closed periods.  In accordance with the European Market Abuse Regulation, the Company will inform the market of...

COMMENTARY FROM MANAGEMENT Second-quarter revenue for Merko Ehitus was EUR 86 million and net profit was EUR 6.4 million. The revenue for first half increased by 12% to EUR 146 million and net profit by 19% to EUR 9.8 million. This year, Merko has sold nearly 150 apartments this year and launched the construction of more than 800 apartments. According to the management of Merko Ehitus, the construction sector is more and more influenced by the rapid price rise of materials and problems related to supply, as a result of which the risks related to on-time completion of construction objects and staying within budget have soared. Considering the current market situation, the management is satisfied with the results of the first half of the year. The group’s revenue and net profit grew in both Q2 and in the first half of the year. The number...

Hexagon Ragasco, a Hexagon company and world leading manufacturer of LPG composite cylinders – was awarded an Environmental Product Declaration (EPD) from EPD–Norway for the production of its cylinders. Hexagon Ragasco’s cylinders are produced at the company’s fully automated manufacturing plant in Raufoss, Norway. In the past 21 years, Hexagon Ragasco has sold over 19 million cylinders in over 85 countries. Value of an Environmental Product Declaration (EPD) An EPD discloses a product’s life cycle environmental impact and helps users to identify sustainable products. Both the underlying Life-Cycle Assessment (LCA) and the EPD are based upon international standards. Furthermore, it contains quantified information that enables comparison between products from the same product category and declares its environmental footprint towards...

Press Release Outside trading hours – Regulated information* Brussels, 5 August 2021 (07.00 a.m. CEST)          KBC Group: Second-quarter result of 793 million euros In many countries, the large-scale rollout of vaccines that started in the first quarter of 2021 is now running at full speed. While caution is still paramount, the general feeling is one of anticipation for a long-awaited, full resumption of social activities, and optimism for a worldwide economic recovery. From the start of this crisis almost a year and a half ago, we have taken responsibility in safeguarding the health of our staff and customers, while ensuring that services continue to be provided. We have also worked closely with government agencies to support all customers impacted by the coronavirus, implementing various measures such as loan deferrals. Besides...

Pivotal study VLA1553-301 met its primary endpoint Vaccine candidate induced protective CHIKV neutralizing antibody titers in 98.5% of subjects after a single vaccination VLA1553 was well tolerated across all age groups Final trial results expected within the next six monthsSaint Herblain (France), August 5, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced positive topline results from the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553. VLA1553 was recently awarded Breakthrough Designation status by the Food and Drug Administration (FDA). The trial, involving 4,115 adults, aged 18 years and above, across 44 sites in the...

Strong cash and cash equivalents position at June 30, 2021 of CHF18.1M ($19.6M) Pivotal dipraglurant PD-LID study initiated Janssen Pharmaceuticals started Phase 2 study in epilepsy with ADX71149 Dipraglurant blepharospasm study on track to start in Q3 2021 Completed $11.5M fundraising in January 2021Geneva, Switzerland, August 5, 2021 – Ad Hoc Announcement Pursuant to Art. 53 LR Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its half-year and second quarter financial results for the periods ended June 30, 2021 and provided a corporate update. “We started two clinical studies in the last 60-days, which includes our internal dipraglurant program in dyskinesia associated with Parkinson’s disease (PD-LID)...

August 5, 2021 Record–breaking backlog, increased shareholder returns, positioning for New Energy HighlightsFinancial results in line with management expectations Record-level US$29.5 billion proforma backlog, up by c. US$8 billion Launch of EUR150 million (c. US$180 million) share repurchase program Scaling-up renewables: 200 MW floating offshore wind development 2021 Directional1 revenue guidance maintained at around US$2.6 billion 2021 Directional EBITDA guidance maintained at around US$900 millionThe 2021 Half Year Results and Interim Financial Statements are published on the Company’s website under https://www.sbmoffshore.com/investor-relations-centre/financial-information/financial-results/half-year-results/. Bruno Chabas, CEO of SBM Offshore, commented: “All our three value platforms, Ocean Infrastructure, Growing the...

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 5 August 2021 Fagron reports turnover of € 276.6 million Accelerated growth at Fagron Sterile Services in Wichita – turnover target raised on acquisition of US Compounding activities Financial highlights of H1 2021Turnover decreased 0.8% to € 276.6 million (+5.9% at constant exchange rates) Gross margin decreased 140 bps to 58.4% due to temporary COVID-related impact REBITDA1 decreased 11.0% to € 56.0 million REBITDA margin decreased to 20.2% (H1 2020: 22.6%) EBIT decreased 11.9% to € 40.7 million Operating cash flow increased 15.1% to € 31.3 million Net financial debt /REBITDA ratio of 2.18 at 30 June 2021 Outlook for 2021: Further turnover growth with a REBITDA between € 118 and € 124 million Strategic and operational highlightsWichita compounding facility on...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 04, 2021 (GLOBE NEWSWIRE) — Melior Resources Inc. (TSXV: “MLR”) (“Melior” or the “Company”) is pleased to announce that Ranchero Gold Corp. (“Ranchero”) has closed the second tranche of its previously announced private placement (the “Concurrent Financing”) through the offering of an additional 454,545 subscription receipts (each, a “Subscription Receipt”) at a purchase price of $0.55 per Subscription Receipt for gross proceeds of $250,000. In total, Ranchero has issued an aggregate of 9,561,613 Subscription Receipts under the Concurrent Financing for aggregate gross proceeds of $5,258,887. No finders’ fees were paid in connection with this second tranche of the Concurrent Financing. Please see the...

PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, acknowledges today with great sorrow that Tadataka (Tachi) Yamada, M.D., founder and chairman of the board for Passage Bio, passed away unexpectedly on August 3, 2021. “We are deeply saddened by the sudden passing of Tachi, a visionary leader in our field and co-founder of Passage Bio,” said Bruce Goldsmith, Ph.D., president and CEO, Passage Bio. “We are forever grateful for the vision, scientific experience, and strategic influence that he shared to establish our company. He has left a lasting legacy with his generous contribution to our industry, and specifically to Passage Bio and the patients we serve. We will continue...